Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Receivables: 2022-2025

Historic Change in Receivables for Rhythm Pharmaceuticals (RYTM) over the last 3 years, with Sep 2025 value amounting to $6.6 million.

  • Rhythm Pharmaceuticals' Change in Receivables rose 286.42% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year increase of 171.79%. This contributed to the annual value of $3.6 million for FY2024, which is 57.83% down from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Change in Receivables stood at $6.6 million for Q3 2025, which was down 15.73% from $7.8 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Change in Receivables peaked at $7.8 million during Q2 2025, and registered a low of -$794,000 during Q4 2024.
  • For the 3-year period, Rhythm Pharmaceuticals' Change in Receivables averaged around $2.4 million, with its median value being $1.7 million (2024).
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 343.56% in 2024, then skyrocketed by 286.42% in 2025.
  • Rhythm Pharmaceuticals' Change in Receivables (Quarterly) stood at $2.9 million in 2022, then crashed by 88.74% to $326,000 in 2023, then tumbled by 343.56% to -$794,000 in 2024, then spiked by 286.42% to $6.6 million in 2025.
  • Its Change in Receivables stands at $6.6 million for Q3 2025, versus $7.8 million for Q2 2025 and -$687,000 for Q1 2025.